eQTL and multi-omics integration reveal PPIH as a prognostic and immunotherapeutic biomarker
This study highlights PPIH as a candidate biomarker with pan-cancer relevance and potential clinical value. These findings offer new directions for cancer diagnosis and provide a foundation for further development of targeted therapeutic approaches.
Authors
- Yanmei Wu (ORCID: https://orcid.org/0000-0002-2177-9098)
- Wei Wang (ORCID: https://orcid.org/0000-0001-7289-4822)
- Xinlu Zhang (ORCID: https://orcid.org/0000-0001-7668-091X)
- Fenglin Lv (ORCID: https://orcid.org/0000-0001-6321-4936)
- Huaxin Zhou (ORCID: https://orcid.org/0000-0003-4341-0686)
- X. Zheng
- Zhongyu Li (ORCID: https://orcid.org/0000-0003-0961-6162)
Institutions
- Second Hospital of Shandong University (CN)
- Jinan Central Hospital (CN)
- Center for High Pressure Science & Technology Advanced Research (CN)
- Shandong Maternal and Child Health Hospital (CN)
- Shandong First Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-08-14
- DOI
- https://doi.org/10.3389/fimmu.2025.1647722
- Primary Topic
- Hepatitis C virus research
- Type
- article
- Field-Weighted Citation Impact
- 0.00